The Society for Immunotherapy of Cancer (SITC) published the first Clinical Practice Guideline (CPG) on immunotherapy for the treatment of Cutaneous Melanoma in Nature Reviews Clinical Oncology in 2013. On May 30, 2018, SITC published an update in the Journal for ImmunoTherapy of Cancer (JITC), the society's open access, peer-reviewed online journal. SITC's Cancer Immunotherapy Guidelines program is a collection of CPGs developed by multi-disciplinary panels of experts who draw from their own practical experience as well as evidence in the published literature and clinical trial data to develop evidence- and consensus-based recommendations. SITC uses as a model the Institute of Medicine's 2011 "Standards for Developing Trustworthy Clinical Practice Guidelines" to ensure the recommendations are unbiased, transparent and balanced will aid oncologists in effective clinical decision-making concerning patient selection, toxicity management, response evaluation, and the sequencing or combination of therapies, among other topics. This update to the Cutaneous Melanoma CPG was developed collaboratively through the efforts of an expert panel that convened to discuss the current therapeutic landscape. This CPG provides recommendations for the use of immunotherapies including checkpoint inhibitor monotherapies and combinations, as well as oncolytic viruses, interferon-α2, and interleukin-2 in various disease stages and settings. Additionally, the CPG include discussion for patient selection, sequencing or combination of therapies, using and screening for predictive biomarkers, managing adverse events, selecting optimal clinical endpoints, and patient quality of life issues.
Published May 30, 2018 in Journal for ImmunoTherapy of Cancer (JITC) as "An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0."Updated July 27, 2018 Current treatment algorithms for the SITC Cancer Immunotherapy Guidelines - Cutaneous Melanoma.
Learn more about immunotherapy treatment standards for cutaneous melanoma and hear about the recently updated Society for Immunotherapy of Cancer's consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma in this free one-hour webinar. SITC hosted this session on Monday, July 30, 2018, featuring members of the Cancer Immunotherapy Guideline – Melanoma Expert Panel.VIEW ON-DEMAND WEBINAR
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: email@example.com